Replies to post #228119 on Biotech Values

[DewDiligence]

Re: Amended BMY-NKTR deal

This following sentence, buried within the bowels of the press release, is curious:

Also as part of the new strategic collaboration agreement, Bristol-Myers Squibb will independently conduct and fund a Phase 1/2 dose optimization and expansion study in first-line non-small-cell lung cancer with bempeg and nivolumab.

Emphasis added.

In the original agreement, BMY didn't do anything with NKTR-214 independently.